Finally, in a prospective study of 238 people with HIV/HCV coinfection (50% with cirrhosis) treated with antiviral therapy (53.4% with PEG-IFN + RBV + DAA; 34.4% PEG-IFN + RBV; 12.2% sofosbuvir + RBV 12.2%), there was no significant effect of HCV cure (n = 145) on BMD at the lumbar spine and femoral neck or biomarkers of bone remodeling, including soluble receptor activator of nuclear factor-κβ ligand or osteoprotegerin [69]. The gene discussed is IFNA1; the disease is Cirrhosis.